{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:43:24Z","timestamp":1785786204733,"version":"3.56.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U2CDA050097"],"award-info":[{"award-number":["U2CDA050097"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.josat.2024.209525","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T18:41:32Z","timestamp":1728499292000},"page":"209525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Factors affecting problem-solving court team decisions about medications for opioid use disorder"],"prefix":"10.1016","volume":"168","author":[{"given":"Barbara","family":"Andraka-Christou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Viglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"del Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle N.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Totaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Pivovarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.josat.2024.209525_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40352-022-00188-4","article-title":"Barriers to medications for opioid use disorder in the court system: provider availability, provider \u201ctrustworthiness,\u201d and cost","volume":"10","author":"Ahmed","year":"2022","journal-title":"Health & Justice"},{"key":"10.1016\/j.josat.2024.209525_bb0015","author":"All Rise"},{"key":"10.1016\/j.josat.2024.209525_bb0020","author":"American Society of Addiction Medicine"},{"key":"10.1016\/j.josat.2024.209525_bb0025","article-title":"Disparities in access to opioid treatment programs and buprenorphine providers by race and ethnicity in the contiguous U.S","volume":"209193","author":"Amiri","year":"2023","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"10.1016\/j.josat.2024.209525_bb0030","first-page":"189","article-title":"What is treatment for opioid addiction in problem-solving courts? A study of 20 Indiana drug & veterans courts","volume":"13","author":"Andraka-Christou","year":"2017","journal-title":"CRCL"},{"issue":"12","key":"10.1016\/j.josat.2024.209525_bb0035","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1080\/10826084.2023.2236201","article-title":"Problem-solving court staff preferences for educational videos about medications for opioid use disorder","volume":"58","author":"Andraka-Christou","year":"2023","journal-title":"Substance Use & Misuse"},{"issue":"6","key":"10.1016\/j.josat.2024.209525_bb0040","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/00952990.2020.1807559","article-title":"Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff","volume":"46","author":"Andraka-Christou","year":"2020","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.josat.2024.209525_bb0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/08897077.2021.1944958","article-title":"Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder","volume":"43","author":"Andraka-Christou","year":"2022","journal-title":"Substance Abuse"},{"issue":"5","key":"10.1016\/j.josat.2024.209525_bb0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/dar.13090","article-title":"Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: A preliminary study of Florida criminal problem-solving and dependency court staff","volume":"39","author":"Andraka-Christou","year":"2020","journal-title":"Drug and Alcohol Review"},{"issue":"1","key":"10.1016\/j.josat.2024.209525_bb0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/08897077.2021.1944958","article-title":"Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder","volume":"43","author":"Andraka-Christou","year":"2022","journal-title":"Substance Abuse"},{"key":"10.1016\/j.josat.2024.209525_bb0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jsat.2019.06.011","article-title":"Court personnel attitudes towards medication-assisted treatment: A state-wide survey","volume":"104","author":"Andraka-Christou","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209525_bb0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40352-022-00178-6","article-title":"A national survey of state laws regarding medications for opioid use disorder in problem-solving courts","volume":"10","author":"Andraka-Christou","year":"2022","journal-title":"Health Justice"},{"key":"10.1016\/j.josat.2024.209525_bb0070","article-title":"Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder","author":"Andrilla","year":"2021","journal-title":"The Journal of Rural Health."},{"issue":"5","key":"10.1016\/j.josat.2024.209525_bb0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/ajad.13439","article-title":"Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study","volume":"32","author":"Bakouni","year":"2023","journal-title":"The American Journal on Addictions"},{"issue":"2","key":"10.1016\/j.josat.2024.209525_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1258\/jhsrp.2009.009081","article-title":"Thematic analysis and its reconceptualization as \u201csaliency analysis\u201d","volume":"15","author":"Buetow","year":"2010","journal-title":"Journal of Health Services Research & Policy"},{"issue":"9","key":"10.1016\/j.josat.2024.209525_bb0085","doi-asserted-by":"crossref","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Network Open"},{"issue":"35","key":"10.1016\/j.josat.2024.209525_bb0090","article-title":"Methadone treatment providers\u2019 views of drug court policy and practice: A case study of New York State","volume":"10","author":"Csete","year":"2013","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.josat.2024.209525_bb0095","series-title":"Painting the current picture: A National Report on treatment courts in the United States","author":"DeVall","year":"2023"},{"key":"10.1016\/j.josat.2024.209525_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2022.100051","article-title":"Insurance barriers to substance use disorder treatment after passage of mental health and addiction parity laws and the affordable care act: A qualitative analysis","volume":"3","author":"Dickson-Gomez","year":"2022","journal-title":"Drug and Alcohol Dependence Reports"},{"issue":"9","key":"10.1016\/j.josat.2024.209525_bb0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.2807","article-title":"Disparities in medication use for criminal justice system-referred opioid use disorder treatment","volume":"5","author":"Donahoe","year":"2024","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.josat.2024.209525_bb0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"Journal of Addiction Medicine"},{"issue":"2","key":"10.1016\/j.josat.2024.209525_bb0115","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/00220426221109948","article-title":"Medication-assisted treatment in problem-solving courts: A national survey of state and local court coordinators","volume":"53","author":"Farago","year":"2022","journal-title":"Journal of Drug Issues"},{"issue":"4","key":"10.1016\/j.josat.2024.209525_bb0120","doi-asserted-by":"crossref","first-page":"e203711","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2024.209525_bb0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0022427806291271","article-title":"How drug treatment courts work: An analysis of mediators","volume":"44","author":"Gottfredson","year":"2007","journal-title":"Journal of Research in Crime and Delinquency"},{"key":"10.1016\/j.josat.2024.209525_bb0130","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000001189","article-title":"Evidence on buprenorphine dose limits: A review","author":"Grande","year":"2023","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2024.209525_bb0135","series-title":"To grow market share, a drugmaker pitches its product to judges","author":"Harper","year":"2021"},{"issue":"2","key":"10.1016\/j.josat.2024.209525_bb0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"8","key":"10.1016\/j.josat.2024.209525_bb0145","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/10509674.2013.782936","article-title":"Individual patient and program factors related to prison and community treatment completion in prison-initiated methadone maintenance treatment","volume":"52","author":"Kinlock","year":"2013","journal-title":"Journal of Offender Rehabilitation"},{"key":"10.1016\/j.josat.2024.209525_bb0150","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1377\/hlthaff.2017.0890","article-title":"Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine","volume":"36","author":"Krawczyk","year":"2017","journal-title":"Health Affairs"},{"issue":"3","key":"10.1016\/j.josat.2024.209525_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.josat.2024.209525_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2024.104318","article-title":"Association between high-threshold practices and buprenorphine treatment termination","volume":"124","author":"Lyle","year":"2024","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.josat.2024.209525_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108850","article-title":"Drug court utilization of medications for opioid use disorder in high opioid mortality communities","volume":"141","author":"Marlowe","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209525_bb0170","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jsat.2012.10.004","article-title":"Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes","volume":"44","author":"Matusow","year":"2013","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"10","key":"10.1016\/j.josat.2024.209525_bb0175","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1080\/10826084.2021.1936045","article-title":"Online medication assisted treatment education for court professionals: Need, opportunities and challenges","volume":"56","author":"Matusow","year":"2021","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.josat.2024.209525_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109084","article-title":"Do people with opioid use disorder and posttraumatic stress disorder benefit from adding individual opioid drug counseling to buprenorphine?","volume":"228","author":"McHugh","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.josat.2024.209525_bb0185","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1176\/appi.ps.202000565","article-title":"How physician workforce shortages are hampering the response to the opioid crisis","volume":"73","author":"McNeely","year":"2022","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.josat.2024.209525_bb0190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jsat.2019.07.013","article-title":"Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact","volume":"108","author":"Miele","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2024.209525_bb0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Affairs (Millwood)"},{"key":"10.1016\/j.josat.2024.209525_bb0200","author":"National Association of Drug Court Professionals"},{"key":"10.1016\/j.josat.2024.209525_bb0205","author":"National Association of Drug Court Professionals"},{"issue":"6","key":"10.1016\/j.josat.2024.209525_bb0210","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/add.13314","article-title":"Iterative categorization (IC): A systematic technique for analysing qualitative data","volume":"111","author":"Neale","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2024.209525_bb0215","series-title":"Neither justice nor treatment: Drug courts in the United States","author":"Physicians for Human Rights","year":"2017"},{"key":"10.1016\/j.josat.2024.209525_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2022.208950","article-title":"Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers","volume":"147","author":"Pivovarova","year":"2023","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"10.1016\/j.josat.2024.209525_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108155","article-title":"Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic","volume":"120","author":"Pytell","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209525_bb0230","author":"Qualtrics [Computer software]"},{"issue":"6","key":"10.1016\/j.josat.2024.209525_bb0235","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8279","article-title":"Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: A systematic review and meta-analysis","volume":"3","author":"Ray","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209525_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102704","article-title":"\u201cYou are not clean until you\u2019re not on anything\u201d: Perceptions of medication-assisted treatment in rural Appalachia","volume":"85","author":"Richard","year":"2020","journal-title":"The International Journal on Drug Policy"},{"issue":"1","key":"10.1016\/j.josat.2024.209525_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11292-020-09421-2","article-title":"How do drug courts work?","volume":"16","author":"Roman","year":"2020","journal-title":"Journal of Experimental Criminology"},{"issue":"9","key":"10.1016\/j.josat.2024.209525_bb0250","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2024.209525_bb0255","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ypmed.2015.04.002","article-title":"Vermont responds to its opioid crisis","volume":"80","author":"Simpatico","year":"2015","journal-title":"Preventive Medicine"},{"key":"10.1016\/j.josat.2024.209525_bb0260","article-title":"Viewing then doing?: Problem-solving court coordinators\u2019 perceptions of medications for opioid use disorders from a nationally representative survey in the United States","volume":"1-9","author":"Smith","year":"2023","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.josat.2024.209525_bb0265","author":"SocioCultural Research Consultants"},{"key":"10.1016\/j.josat.2024.209525_bb0270","author":"Substance Abuse & Mental Health Services Administration"},{"key":"10.1016\/j.josat.2024.209525_bb0275","series-title":"Treatment improvement protocol (TIP) series 63, full document","article-title":"Medications for opioid use disorder","author":"Substance Abuse and Mental Health Services Administration","year":"2018"},{"key":"10.1016\/j.josat.2024.209525_bb0280","series-title":"Use of medication-assisted treatment for opioid use disorder in criminal justice settings","author":"Substance Abuse and Mental Health Services Administration","year":"2019"},{"key":"10.1016\/j.josat.2024.209525_bb0285","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.josat.2024.209525_bb0290","author":"Supreme Court of Florida"},{"key":"10.1016\/j.josat.2024.209525_bb0295","series-title":"Comparative study and evaluation of SCRAM use, recidivism rates, and characteristics","author":"Tison","year":"2015"},{"key":"10.1016\/j.josat.2024.209525_bb0300","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"International Journal for Quality in Health Care"},{"issue":"3","key":"10.1016\/j.josat.2024.209525_bb0305","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10509674.2019.1706687","article-title":"Trauma exposure and post-traumatic stress symptoms among men and women in a substance use and mental health treatment court sample","volume":"59","author":"Tossone","year":"2020","journal-title":"Journal of Offender Rehabilitation"},{"key":"10.1016\/j.josat.2024.209525_bb0310","author":"U.S. Bureau of Justice Assistance"},{"key":"10.1016\/j.josat.2024.209525_bb0315","author":"US Department of Justice"},{"issue":"2","key":"10.1016\/j.josat.2024.209525_bb0320","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209525_bb0325","article-title":"Critical factors influencing interorganizational relationships between juvenile probation and behavioral health agencies","author":"Welsh","year":"2020","journal-title":"Administration and Policy in Mental Health"},{"key":"10.1016\/j.josat.2024.209525_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108923","article-title":"Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence","volume":"228","author":"Wyse","year":"2021","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924002376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924002376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T04:58:43Z","timestamp":1733288323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924002376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":65,"alternative-id":["S2949875924002376"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209525","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors affecting problem-solving court team decisions about medications for opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209525"}}